Levy Y, Klein L, Aviram M, Brook G J, Cogan U
Lipid Research Unit, Rambam Medical Center, Haifa, Israel.
Scand J Clin Lab Invest. 1992 Nov;52(7):671-7. doi: 10.3109/00365519209115512.
Lovastatin was administered to six hypercholesterolaemic patients (mean plasma cholesterol 450 mg dl-1). Plasma lipoproteins (VLDL, LDL, and HDL) were separated before and following 7 and 12 weeks treatment with lovastatin. Fluidity was quantified by fluorescence polarization measurements using 1,6-diphenyl 1,3,5 hexatriene (DPH) as the fluorescent probe. Lovastatin treatment resulted in a significant reduction of total plasma cholesterol, LDL cholesterol and VLDL cholesterol (-41%, -44%, -68%, respectively). Fluidity measurements showed significant (p < 0.01) increase in LDL fluidity by 11% and 21% after 7 and 12 weeks of lovastatin treatment, whereas, VLDL fluidity was increased by 27% after 12 weeks of therapy. HDL fluidity was not altered. These alterations in the fluidity of the atherogenic lipoproteins (LDL and VLDL) in hypercholesterolaemic patients may prove to be of significance in reducing the risk of atherosclerosis.
洛伐他汀被给予6名高胆固醇血症患者（平均血浆胆固醇450mg/dl-1）。在用洛伐他汀治疗7周和12周之前及之后，分离血浆脂蛋白（极低密度脂蛋白、低密度脂蛋白和高密度脂蛋白）。使用1,6-二苯基-1,3,5-己三烯（DPH）作为荧光探针，通过荧光偏振测量对流动性进行定量。洛伐他汀治疗导致血浆总胆固醇、低密度脂蛋白胆固醇和极低密度脂蛋白胆固醇显著降低（分别降低41%、44%、68%）。流动性测量显示，在洛伐他汀治疗7周和12周后，低密度脂蛋白流动性显著增加（p<0.01），分别增加11%和21%，而在治疗12周后，极低密度脂蛋白流动性增加27%。高密度脂蛋白流动性未改变。高胆固醇血症患者中致动脉粥样硬化脂蛋白（低密度脂蛋白和极低密度脂蛋白）流动性的这些改变可能对降低动脉粥样硬化风险具有重要意义。
